erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
.
tel - ??????
.
.
., seventh-highest in the nation, and more than double the national average.
.